On World Kidney Day, doctors say urine can reveal early kidney warning signs. Healthy urine is pale yellow, but dark, red, brown, or persistently frothy urine may indicate dehydration, infections, ...

On World Kidney Day 2026, nephrologist Dr Vaishnavi explains how changes in urine colour, frequency and foam can signal early kidney problems and why early testing is important.

For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein to creatinine ratio (UPCR) and achieved a ...

Vertex Pharmaceuticals (VRTX) stock climbed 5% after povetacicept showed strong phase 3 results in IgA nephropathy, with FDA filing planned by March.

Incidental detection has increased with ubiquitous CT/MRI, inflating early-stage ‘small renal mass’ diagnoses and complicating interpretation of a ~5% rise in <50-year incidence. Obesity, hypertension ...

We are continuing to see an increase in the incidence of kidney cancer in younger patients over time. Maintaining kidney health involves basic lifestyle choices: avoiding obesity, not smoking, and ...

Johnson & Johnson today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with ...

Vertex reported a phase 3 win for its kidney disease prospect povetacicept, meeting analyst expectations and firing the starting gun on a race to the FDA that could result in an accelerated approval ...

Vertex Pharmaceuticals Inc VRTX shares are rising in extended trading Monday after the company announced positive interim results for one of its Phase 3 trials. Vertex Pharmaceuticals stock is trading ...

Vertex Pharmaceuticals Inc. VRTX shares are up during Tuesday’s premarket session following positive interim results from one of its Phase 3 trials. The stock’s rise comes as the company is reportedly ...

Investing.com -- Relmada Therapeutics, Inc. (NASDAQ:RLMD) shares rose 25% Monday following the company’s announcement of 12-month interim data from its Phase 2 trial evaluating NDV-01 in patients with ...

Relmada Therapeutics stock surged after reporting positive Phase 2 trial results for NDV-01 and announcing a $160 million ...